Published in Cancer Metastasis Rev on December 01, 2010
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma. Eur Urol (2012) 1.69
Activation of two distinct Sox9-EGFP-expressing intestinal stem cell populations during crypt regeneration after irradiation. Am J Physiol Gastrointest Liver Physiol (2012) 1.67
Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A (2011) 1.58
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther (2013) 1.44
Mesenchymal stromal cell secretome up-regulates 47 kDa CXCR4 expression, and induce invasiveness in neuroblastoma cell lines. PLoS One (2015) 1.42
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res (2011) 1.42
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol (2012) 1.37
SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett (2012) 1.34
Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res (2013) 1.14
The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol Cancer (2011) 1.13
Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer (2014) 1.11
The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol (2011) 1.08
Cooperative roles of SDF-1α and EGF gradients on tumor cell migration revealed by a robust 3D microfluidic model. PLoS One (2013) 1.07
Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives. Front Immunol (2015) 1.05
The intricate role of CXCR4 in cancer. Adv Cancer Res (2014) 1.04
Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev (2013) 1.04
Sequence-specific recruitment of heterochromatin protein 1 via interaction with Krüppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. J Biol Chem (2012) 1.03
A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Mol Cancer Ther (2012) 1.02
CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells. Mol Cancer Res (2013) 1.02
Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget (2014) 1.02
Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev (2012) 1.01
Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron (2011) 1.01
Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A (2013) 1.00
Ubiquitination of CXCR7 controls receptor trafficking. PLoS One (2012) 1.00
Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget (2015) 0.99
Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS One (2012) 0.98
Brain tumor stem cell multipotency correlates with nanog expression and extent of passaging in human glioblastoma xenografts. Oncotarget (2013) 0.96
IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-κB signaling. J Clin Invest (2015) 0.95
Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep (2015) 0.94
Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol (2012) 0.94
Induction of C-X-C chemokine receptor type 7 (CXCR7) switches stromal cell-derived factor-1 (SDF-1) signaling and phagocytic activity in macrophages linked to atherosclerosis. J Biol Chem (2013) 0.94
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One (2013) 0.92
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis. J Exp Clin Cancer Res (2015) 0.91
AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev (2014) 0.91
Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation. Mol Cell Proteomics (2015) 0.90
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues. J Biol Chem (2012) 0.89
A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer(1,2.) Transl Oncol (2014) 0.89
Quantitative phosphoproteomics of CXCL12 (SDF-1) signaling. PLoS One (2011) 0.88
NMR metabolomics of MTLn3E breast cancer cells identifies a role for CXCR4 in lipid and choline regulation. J Proteome Res (2012) 0.88
CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin Exp Metastasis (2011) 0.88
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget (2015) 0.88
CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br J Cancer (2012) 0.87
Chemokine and Fgf signalling act as opposing guidance cues in formation of the lateral line primordium. Development (2012) 0.87
CXCR4/CXCL12 in non-small-cell lung cancer metastasis to the brain. Int J Mol Sci (2013) 0.87
Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12. PLoS One (2011) 0.86
CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer. Oncogene (2015) 0.86
Expression and function of CXCR4 in human salivary gland cancers. Clin Exp Metastasis (2012) 0.86
The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncol Lett (2012) 0.86
Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. Int J Clin Exp Pathol (2014) 0.86
High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br J Cancer (2014) 0.85
CXCR7-mediated progression of osteosarcoma in the lungs. Br J Cancer (2013) 0.85
Prostanoid induces premetastatic niche in regional lymph nodes. J Clin Invest (2014) 0.85
Cytosolic phospholipase A(2)α and eicosanoids regulate expression of genes in macrophages involved in host defense and inflammation. PLoS One (2013) 0.85
Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine. J Med Chem (2014) 0.84
Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol (2014) 0.84
Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid. Toxicology (2011) 0.84
Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus. PLoS One (2013) 0.84
CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther (2015) 0.84
Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4. J Chem Inf Model (2014) 0.84
The tumor microenvironment in esophageal cancer. Oncogene (2016) 0.83
CXCR7 expression in esophageal cancer. J Transl Med (2013) 0.83
Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. Neuro Oncol (2014) 0.83
Examination of structure-activity relationship of viologen-based dendrimers as CXCR4 antagonists and gene carriers. Bioconjug Chem (2014) 0.83
Molecular mechanisms of liver metastasis. Int J Clin Oncol (2011) 0.83
Structure-Based Identification of Novel Ligands Targeting Multiple Sites within a Chemokine-G-Protein-Coupled-Receptor Interface. J Med Chem (2016) 0.83
Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice. Cancer Prev Res (Phila) (2015) 0.82
Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction. Curr Top Med Chem (2012) 0.82
Regulatory System for Stem/Progenitor Cell Niches in the Adult Rodent Pituitary. Int J Mol Sci (2016) 0.82
CXCL12/CXCR4 signal axis plays an important role in mediating bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells. Int J Med Sci (2013) 0.82
Knock-down of CD44 regulates endothelial cell differentiation via NFκB-mediated chemokine production. PLoS One (2014) 0.82
Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients. PLoS One (2014) 0.82
Intracellular coexpression of CXC- and CC- chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation. BMC Cancer (2014) 0.81
Dynamic filopodia are required for chemokine-dependent intracellular polarization during guided cell migration in vivo. Elife (2015) 0.81
Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br J Pharmacol (2015) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
The impact of cellular senescence in cancer therapy: is it true or not? Acta Pharmacol Sin (2011) 0.81
AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments. Oncol Rep (2015) 0.81
Oligomannurarate sulfate inhibits CXCL12/SDF-1-mediated proliferation and invasion of human tumor cells in vitro. Acta Pharmacol Sin (2013) 0.81
Grk2 is an essential regulator of CXCR7 signalling in astrocytes. Cell Mol Neurobiol (2012) 0.81
A novel application for a 3-dimensional timelapse assay that distinguishes chemotactic from chemokinetic responses of hematopoietic CD133(+) stem/progenitor cells. Stem Cell Res (2013) 0.81
Cancer Cell Colonisation in the Bone Microenvironment. Int J Mol Sci (2016) 0.81
Association between preeclampsia and the CXC chemokine family (Review). Exp Ther Med (2015) 0.80
Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance. Stem Cells Int (2016) 0.80
Involvement of the nuclear factor-κB signaling pathway in the regulation of CXC chemokine receptor-4 expression in neuroblastoma cells induced by tumor necrosis factor-α. Int J Mol Med (2014) 0.80
Stimulation of TLR4 by LMW-HA induces metastasis in human papillary thyroid carcinoma through CXCR7. Clin Dev Immunol (2013) 0.80
Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. J Cell Biochem (2013) 0.80
G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis. PLoS One (2016) 0.80
PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma. PLoS One (2013) 0.79
Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep (2015) 0.79
Differential expression of SDF-1 isoforms in bladder cancer. J Urol (2013) 0.79
A CXCR4-targeted site-specific antibody-drug conjugate. Angew Chem Int Ed Engl (2014) 0.79
COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration. BMC Cancer (2014) 0.79
Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation. J Cancer (2015) 0.79
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med (2004) 11.71
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (1998) 11.41
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med (1997) 6.39
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol (2002) 6.22
Stem cells and cancer: two faces of eve. Cell (2006) 6.13
The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 5.45
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood (2005) 5.21
Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol (2004) 5.07
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science (1993) 4.64
Control of chemokine-guided cell migration by ligand sequestration. Cell (2008) 4.61
The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol (2004) 4.09
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest (2000) 3.78
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Normal stem cells and cancer stem cells: the niche matters. Cancer Res (2006) 3.60
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med (2003) 3.33
Guidance of primordial germ cell migration by the chemokine SDF-1. Cell (2002) 3.22
CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood (2009) 3.20
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res (2003) 3.03
The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest (1995) 3.00
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J (2004) 2.94
Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A (2009) 2.76
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res (2002) 2.71
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res (2000) 2.61
Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res (2005) 2.59
Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4. Dev Biol (1999) 2.52
CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem (2002) 2.37
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol (2001) 2.33
Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res (2004) 2.31
Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone (2005) 2.30
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med (2008) 2.25
Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev Biol (2007) 2.24
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest (2006) 2.14
Roots and stems: stem cells in cancer. Nat Med (2006) 2.13
CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood (2002) 2.10
Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res (2007) 2.02
AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol (2009) 1.99
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene (2003) 1.96
Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity (2009) 1.95
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene (2005) 1.87
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol (2008) 1.87
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res (2002) 1.84
Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood (2001) 1.76
CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther (2004) 1.74
Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal (2005) 1.65
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis (2007) 1.63
CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer (2007) 1.62
Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res (2001) 1.61
Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nat Cell Biol (2009) 1.61
High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer (2009) 1.55
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54
CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res (2002) 1.52
CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia (2006) 1.52
Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res (2005) 1.48
Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res (2003) 1.45
Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood (2002) 1.45
CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res (2010) 1.44
Imaging ligand-dependent activation of CXCR7. Neoplasia (2009) 1.43
Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene (2006) 1.43
A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res (2007) 1.43
Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer (2009) 1.41
CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell (2005) 1.41
Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochem Biophys Res Commun (1998) 1.41
Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer (2009) 1.39
Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate (2009) 1.37
Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res (2006) 1.35
SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaB-dependent pathway in microglia. Eur J Pharmacol (2009) 1.35
Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett (1998) 1.33
High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res (2007) 1.32
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31
Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep (2009) 1.29
CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol (1998) 1.29
Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol (1999) 1.29
The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep (2009) 1.29
Modulation of the SDF-1-CXCR4 axis by the third complement component (C3)--implications for trafficking of CXCR4+ stem cells. Exp Hematol (2006) 1.28
Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer (2010) 1.28
Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. J Immunol (1999) 1.23
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
PIRSF: family classification system at the Protein Information Resource. Nucleic Acids Res (2004) 19.62
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
The Protein Information Resource: an integrated public resource of functional annotation of proteins. Nucleic Acids Res (2002) 12.20
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
The Protein Information Resource. Nucleic Acids Res (2003) 11.17
PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res (2009) 11.05
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol (2002) 6.22
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Representative proteomes: a stable, scalable and unbiased proteome set for sequence analysis and functional annotation. PLoS One (2011) 5.64
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol (2005) 5.27
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
An overview of the PubChem BioAssay resource. Nucleic Acids Res (2009) 4.75
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell (2004) 3.98
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
PubChem's BioAssay Database. Nucleic Acids Res (2011) 3.74
The Protein Ontology: a structured representation of protein forms and complexes. Nucleic Acids Res (2010) 3.74
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
BioThesaurus: a web-based thesaurus of protein and gene names. Bioinformatics (2005) 3.43
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Recovery of corneal hysteresis after reduction of intraocular pressure in chronic primary angle-closure glaucoma. Am J Ophthalmol (2009) 3.15
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol (2006) 3.12
Predicting protein-protein interactions based only on sequences information. Proc Natl Acad Sci U S A (2007) 3.06
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Coordination of Rab8 and Rab11 in primary ciliogenesis. Proc Natl Acad Sci U S A (2010) 2.88
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81
S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A (2007) 2.77
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A (2002) 2.65
Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood (2007) 2.65
Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer (2009) 2.64
Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Amine-controlled assembly of metal-sulfite architecture from 1D chains to 3D framework. Inorg Chem (2007) 2.57
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Plasmon-controlled fluorescence: a new paradigm in fluorescence spectroscopy. Analyst (2008) 2.45
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41
Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. Nat Cell Biol (2010) 2.37
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
The yak genome and adaptation to life at high altitude. Nat Genet (2012) 2.34
Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants. PLoS Biol (2007) 2.34
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res (2007) 2.31
Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol (2002) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
Genome-wide association study dissects the genetic architecture of oil biosynthesis in maize kernels. Nat Genet (2012) 2.25
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer (2010) 2.20
An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A (2005) 2.18
Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke (2008) 2.18
Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol (2007) 2.16
PubChem BioAssay: 2014 update. Nucleic Acids Res (2013) 2.14
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Exo70 interacts with phospholipids and mediates the targeting of the exocyst to the plasma membrane. EMBO J (2007) 2.03
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res (2003) 2.00
Membrane association and functional regulation of Sec3 by phospholipids and Cdc42. J Cell Biol (2008) 1.99
Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res (2003) 1.97
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
DNA-nanoparticle superlattices formed from anisotropic building blocks. Nat Mater (2010) 1.92
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91
Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate (2006) 1.90
Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85
Synthesis, structure, and luminescent properties of hybrid inorganic-organic framework materials formed by lead aromatic carboxylates: inorganic connectivity variation from 0D to 3D. Inorg Chem (2009) 1.85
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
LEAFY COTYLEDON1 is a key regulator of fatty acid biosynthesis in Arabidopsis. Plant Physiol (2008) 1.79
Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res (2007) 1.79